Last week, Stellar Pharmaceuticals, Inc. (PINK:SLXCF) had a fantastic Friday after issuing a press release with exciting news.
SLXCF said that Health Canada had granted Tribute Pharmaceuticals, a wholly-owned subsidiary, an approval for CAMBIA, a product for the acute treatment of migraine attacks.
The company stock surged suddenly. Most of the volume came at the news and the high of day followed in about 20 minutes. However, by the end of the session SLXCF had retreated to $0.60, still up 40.52%.[BANNER]
The company also said there would be a conference call held today. In another press release from about two hours ago the company gave details about the call which will be hosted at 4:00 p.m. EDT.
Despite the excitement and anticipation, at the time of this writing SLXCF is down 10%. There is still plenty of time until the call, and the full extent of its impact will likely come tomorrow.
